【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於老年人 (除非用於思覺失調、雙極症、或化療止吐)。

思覺失調症
1. Gilles de la Tourette's syndrome
2. Hyperactive behavior: After failure to respond to non-antipsychotic medication and psychotherapy
3. Problematic behavior in children (Severe): After failure to respond non-antipsychotic medication or psychotherapy
4. Schizophrenia

First Generation (Typical) Antipsychotic
Haloperidol is a butyrophenone antipsychotic whose mechanism of action is not clearly established

1. Comatose state from any cause
2. Hypersensitivity to haloperidol
3. Parkinson disease
4. Severe toxic central nervous system depression

C

Breastfeeding is not recommended by the manufacturer.

Common
Hypotension, Constipation, Xerostomia, Akathisia, Extrapyramidal disease (Frequent ), Somnolence, Blurred vision
Serious
Prolonged QT interval, Sudden cardiac death, Torsades de pointes, Paralytic ileus, Agranulocytosis, Dystonia, Neuroleptic malignant syndrome, Seizure, Tardive dyskinesia, Priapism

General Dosage Information:
1. When converting from injectable to oral haloperidol, give the first oral dose within 12 to 24 hours following the last parenteral dose and adjust the dose to clinical effect.
2. Once stabilization is achieved, maintenance dose should be gradually reduced to lowest effective dose.
3. Use caution if treating patients with QT-prolonging conditions, concomitant QT-prolonging drugs, underlying cardiac abnormalities, hypothyroidism, familial long QT syndrome; older adults (Beers Criteria)

Gilles de la Tourette's syndrome:
1. Moderate symptomatology: 0.5 to 2 mg ORALLY 2 or 3 times daily, higher doses may be required
2. Severe symptomatology: chronic or resistant disease: 3 to 5 mg ORALLY 2 or 3 times daily, higher doses may be required; doses of 100 mg or greater have been used in severely resistant patients, but safety of prolonged use of such large doses has not been shown in limited clinical usage
Schizophrenia:
1. Moderate symptomatology: 0.5 to 2 mg orally 2 to 3 times daily, higher doses may be required
2. Severe symptomatology, chronic or resistant disease: 3 to 5 mg orally 2 or 3 times daily, higher doses may be required; MAX, 100 mg/day or greater has been used in severely resistant patients, but safety of prolonged use of such large doses has not been shown in limited clinical usage
3. Moderate to severe symptomatology, chronic or resistant disease: 4 to 20 mg/day (off-label dosage)

3 to 12 years and 15 to 40 kg:
1. Initial 0.5 mg/day divided and given ORALLY 2 or 3 times daily; may increase daily dose by an increment of 0.5 mg once every 5 to 7 days until desired response
2. Maintenance, usual dose range of 0.05 to 0.075 mg/kg/day ORALLY; upon stabilization, dose should be gradually reduced to lowest effective dose; MAX dose not established, but behavioral improvement is not expected beyond 6 mg/day.
Older than 12 years:
1. Moderate symptomatology: 0.5 to 2 mg ORALLY 2 or 3 times daily, higher doses may be required
2. Severe symptomatology, chronic or resistant disease: 3 to 5 mg ORALLY 2 or 3 times daily, higher doses may be required; doses of 100 mg or greater have been used in severely resistant patients, but safety of prolonged use of such large doses has not been shown in limited clinical usage

Data not available

Data not available

Store at controlled room temperature, between 20 and 25 degrees C; in a tight, light-resistant container